G20 Global Pharma Summit Series-Russia

During C0VID- 19, assiduity growth has laggardly- down, detention in blessings, and tone- adequacy in pharm- product force chain and trend changes in consumption of health- request products along with ethical extremity could be anticipated as long- term impacts of COVID- 19 epidemic on the pharmaceutical sector in both global and original situations.

Seven Major Risks Pharmaceutical Companies Will Face Soon:

• Reduced demand for prescription medicine
• Increased competition
• Customer expectations are evolving
• Supply chain and logistics disruptions
• Counterfeit molecules
• Data breaches and cybersecurity threats
• Antiquated, unfit business models